Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro

Takata,Takanobu; Ishigaki,Yasuhito; Shimasaki,Takeo; Tsuchida,Hideyuki; Motoo,Yoshiharu; Hayashi,Akio; Tomosugi,Naohisa

doi:10.3892/or.2012.2020

Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro

Authors:
- Takanobu Takata
- Yasuhito Ishigaki
- Takeo Shimasaki
- Hideyuki Tsuchida
- Yoshiharu Motoo
- Akio Hayashi
- Naohisa Tomosugi
View Affiliations

Affiliations: Medical Research Institute, Kanazawa Medical University, Uchinada, Japan, Department of Advanced Medicine, Kanazawa Medical University, Hachioji 192-8510, Japan, Agilent Technologies Japan, Ltd., Takakura, Hachioji 192-8510, Japan
Published online on: September 5, 2012 https://doi.org/10.3892/or.2012.2020
Pages: 1968-1976
Copyright: © Takata et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is one of the most lethal cancers, with an incidence equaling mortality. It is a heterogeneous group of neoplasms in which pancreatic ductal adenocarcinoma is most common. Pancreatic cancer cannot be cured even if detected early. When treatment is initiated, a suitable method of administration of anticancer drugs must be chosen. Anticancer drugs kill tumor cells. However, side effects including initiation are problematic in anticancer drug therapy. Improved methods for the diagnosis of side effects of pancreatic cancer by using sensitive and specific tumor markers are highly desirable. Therefore, efficient strategies for biomarker discovery are urgently needed. Here, we present an approach based on direct experimental access to proteins released by PANC-1 human pancreatic cancer cells in vitro. A two-dimensional (2-D) map and catalog of this subproteome, herein termed the secretome, were established comprising more than 1,000 proteins observed by ‘2-D difference in-gel electrophoresis analysis using cyanine dye’. We investigated 22 spots that were 1.20-fold upregulated and 31 spots that were 0.66-fold downregulated by gemcitabine chloride treatment. Proteins in these spots were identified by nano-high-performance liquid chromatography electrospray ionization time of flight mass spectrometry/mass spectrometry. Most secretome constituents were nominally cellular proteins. By mass spectrometry screening, 14-3-3 protein sigma (14-3-3 σ), protein S100-A8, protein S100-A9, galectin-7, lactotransferrin (lactoferrin, LF) precursor, serotransferrin (transferrin) precursor, and vitamin D binding protein precursor were identified. Western blotting confirmed the presence of 14-3-3 σ and LF. We found that upregulation of 14-3-3 σ was associated with apoptosis, and downregulation of LF was found to suppress tumorigenesis.

View Figures

View References

1	Haugk B: Pancreatic intraepithelial neoplasia - can we detect early pancreatic cancer? Histopahology. 57:503–514. 2010. View Article : Google Scholar : PubMed/NCBI
2	Tanaka M, Javel M, Dong X, Eng C, Abbruzzese JL and Li D: Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 116:5325–5335. 2010. View Article : Google Scholar : PubMed/NCBI
3	Shimasaki T, Ishigaki Y, Minamoto T and Motoo R: The influence of expression of Apopthosis related genes in pancreatic cell lines treated with gemcitabine hydrochrolide. Suizo. 22:14–20. 2007. View Article : Google Scholar
4	Wallentine JC, Kim KK, Seiler CE III, Vaughn CP, Crockett DK, Tripp SR, Elenitoba-Johnson KS and Lim MS: Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS. Lab Invest. 87:1113–1124. 2007. View Article : Google Scholar : PubMed/NCBI
5	Xue H, Lu B and Lai M: The cancer secretome: a reservoir of biomarkers. J Trans Med. 6:1–12. 2008.PubMed/NCBI
6	Soares JCS, Santos MF, Trrugilho MRO, Neves-Ferreira AGG, Perales J and Domont GB: Differential proteomics of the plasma of individuals with sepsis caused by Acinetobacter bumannii. J Proteomics. 73:267–278. 2009. View Article : Google Scholar : PubMed/NCBI
7	Mares J, Thongboonkerd V, Tuma Z, Moravec J, Karvunidis T and Matejovic M: Proteomic analysis of proteins bound to adsorption units of extracorporeal liver support system under clinical conditions. J Proteome Res. 8:1756–1764. 2008. View Article : Google Scholar
8	Sun Q, Sha H, Yang X, Bao G, Lu J and Xie Y: Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol. J Cancer Res Clin Oncol. 137:521–532. 2010. View Article : Google Scholar : PubMed/NCBI
9	Shi J, Zen Y and Zheng R: Proteome profiling of early seed development in Cunninghamia lanceolata (Lamb.) Hook. J Exp Bot. 61:2367–2381. 2010. View Article : Google Scholar : PubMed/NCBI
10	Oshita F, Morita A, Ito H, Kameda Y, Tsuchiya E, Shigeru A and Miyagi Y: Proteomic screening of completely resected tumors in relation to survival in patients with stage I non-small cell lung cancer. Oncol Rep. 24:637–645. 2010. View Article : Google Scholar : PubMed/NCBI
11	Varo I, Rigos G, Navarro JC, del Ramo J, Giner C, Hernandez A, Pertusa J and Torreblanca A: Effect of ivermectin on the liver of gilthead sea bream Sparus aurata: a proteomic approach. Chemosphere. 80:570–577. 2010. View Article : Google Scholar : PubMed/NCBI
12	Schagger H and von Jagow W: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 166:368–379. 1987. View Article : Google Scholar : PubMed/NCBI
13	Chillini C, Cochet O, Negroni L, Samson M, Poggi M, Ailhaud G, Alessi MC, Dani C and Amri EZ: Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol Biol. 9:1–16. 2008.PubMed/NCBI
14	Hathout Y: Approaches to the study of the cell secretome. Expert Rev Proteomics. 4:239–248. 2007. View Article : Google Scholar : PubMed/NCBI
15	Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, et al: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 5:157–171. 2006. View Article : Google Scholar : PubMed/NCBI
16	Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, Arenbrg DA, Reddy RC, Akulapalli S, Thannickal VJ, et al: Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res. 5:1143–1154. 2006. View Article : Google Scholar
17	Yamashita R, Fujikawa Y, Ikari K, Hamada K, Otomo A, Yasuda K, Noda M and kaburagi Y: Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry. Mol Cell Biochem. 298:83–92. 2007. View Article : Google Scholar : PubMed/NCBI
18	Wu CC, Chen HC, Chen SJ, Liu HP, Hsieh YY, Yu CJ, Tang R, Hsieh LL, Yu JS and Chang YS: Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics. 8:316–332. 2007.PubMed/NCBI
19	Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, van der Wal T, Luinge M, Alvarez-Llamas G, Vos H, et al: Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 111:2339–2346. 2008. View Article : Google Scholar : PubMed/NCBI
20	Butler GS, Dean RA, Etam EM and Overall CM: Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Mol Cell Biol. 28:4896–4914. 2008. View Article : Google Scholar
21	Sarkissian G, Ferglot P, Lamy PJ, Petard JJ, Culine S, Jouin P, Rioux-Leclercq N and Darbouret B: Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem. 54:574–581. 2008. View Article : Google Scholar : PubMed/NCBI
22	Tunica DG, Yin X, Sidibe A, Stegemann C, Nissum M, Zeng L, Brunet M and May M: Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of free-flow electrophoresis and nanoflow LC-MS/MS. Proteomics. 9:4991–4996. 2009. View Article : Google Scholar : PubMed/NCBI
23	Mohammad DH and Yaffe MB: 14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response. DNA Repair. 8:1009–1017. 2009. View Article : Google Scholar : PubMed/NCBI
24	Morrison DK: The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trens Cell Biol. 19:16–23. 2009. View Article : Google Scholar : PubMed/NCBI
25	Obsilova V, Sihan J, Boura E, Teisinger J and Obsil T: 14-3-3 proteins: a family of versatile molecular regulators. Physiol Res. 57(Suppl 3): S11–S21. 2008.PubMed/NCBI
26	Ferl RJ, Manak MS and Reyes MF: The 14-3-3 σ reviews. Genome Biol. 3:30101–30107. 2002.
27	Yang H, Wen Y, Chen C, Loxano G and Lee M: 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol. 23:7096–7107. 2003. View Article : Google Scholar : PubMed/NCBI
28	Lambiase A, Micera A, Pellegrini G, Merlo D, Rama P, Luca MD and Bonini S: In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression. Invest Ophthalmol Vis Sci. 50:4622–4630. 2009. View Article : Google Scholar : PubMed/NCBI
29	Hermerking H: Extracellular 14-3-3 sigma protein: a potential mediator of epithelial-mesenchymal interactions. J Invest Dermatol. 124:9–10. 2005.PubMed/NCBI
30	Ghahary A, Marcoux Y, Karimi-Busheri F, Li Y, Tredget EE, Kilani RT, Lam E and Weinfeld M: Differentiated keratinocyte-releasable stratifin (14-3-3 sigma) stimulates MMP-1 expression in dermal fibroblasts. J Invest Derrmatol. 122:1188–1197. 2004.PubMed/NCBI
31	Steijns JM and van Hooijdonk AC: Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br J Nutr. 84:11–17. 2000. View Article : Google Scholar : PubMed/NCBI
32	Masson PL, Heremans JF and Dire CH: Lactoferrin, an iron-binding protein in neutrophilic leukocytes. Clin Chim Acta. 14:735–739. 1996.
33	De Vet BJCM and van Gool J: Lactoferrin and iron absorption in the small intestine. Acta Med Scand. 196:393–402. 1974.PubMed/NCBI
34	Mason DY and Taylor CR: Distribution of transferrin, ferritin and lactotranseferrin human tissues. J Clin Pathol. 31:316–327. 1978. View Article : Google Scholar : PubMed/NCBI
35	Brock J: Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant. Arch Dis Child. 55:417–421. 1980. View Article : Google Scholar : PubMed/NCBI
36	Reitamo S, Konttinen YT and Segerberg-Konttinen M: Distribution of lactoferrin in human salivary glands. Histochemistry. 66:285–291. 1980. View Article : Google Scholar : PubMed/NCBI
37	Korsud FR and Brandtzaeg P: Characterization of epithelial elements in human major salivary gland by functional markers: localization of amylase, lactoferrin, lysozyme, secretory component, and secretory immunoglobulins by paired immunofluorescence staining. J Histochem Cytochem. 30:657–666. 1982. View Article : Google Scholar
38	Caselitz J, Jaup T and Seifert G: Lactoferrin and lysozyme in carcinomas of the parotid gland. A comparative immunocytochemical study with the occurrence in normal and inflamed tissue. Virchows Arch A Pathol Anat Histol. 394:61–73. 1981. View Article : Google Scholar : PubMed/NCBI
39	Barresi G and Tuccari G: Lactoferrin in benign hypertrophy and carcinomas of the prostatic gland. Virchows Arch A Pathol Anat Histopathol. 403:59–66. 1984. View Article : Google Scholar : PubMed/NCBI
40	Rossiello R, Carriero MV and Giordano GG: Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J Clin Pathol. 37:51–55. 1984. View Article : Google Scholar : PubMed/NCBI
41	Charpin C, Lachard A, Pourreau SN, Jacquemier J, Lvaut MN, Andonian C, Martin PM and Toga M: Localization of lactoferrin and nonspecific cross-reacting antigen in human breast carcinomas. An immunohistochemical study using the avidin-biotin-peroxidase complex method. Cancer. 55:2612–2617. 1984. View Article : Google Scholar
42	Tuccari G and Barresi G: Immunohistochemical demonstration of lactoferrin in follicular adenomas and thyroid carcinomas. Virchows Arch A Pathol Anat Histopathol. 406:67–74. 1985. View Article : Google Scholar : PubMed/NCBI
43	Baressi G and Tuccari G: Iron-binding proteins in thyroid tumours. An immunocytochemical study. Pathol Res Pract. 182:344–351. 1987. View Article : Google Scholar : PubMed/NCBI
44	Louglin KR, Gittes RF and Patridge D: The relationship of lactoferrin to the anemia of renal carcinoma. Cancer. 59:566–571. 1987. View Article : Google Scholar : PubMed/NCBI
45	Tuccari G, Barresi G, Arena F and Inferrera C: Immunocytochemical detection of lactoferrin in human gastric carcinomas and adenomas. Arch Pathol Lab Med. 113:912–916. 1989.PubMed/NCBI
46	Carbaret V, Vilain MO, Delobelle-Deroide A and Vanseymortier L: Immunohistochemical demonstration of ceruloplasmin and lactoferrin in a series of 59 thyroid tumors. Ann Pathol. 12:347–352. 1992.(In French).
47	Tuccari G, Rizzo A, Crisafulli C and Barresi G: Iron-binding proteins in human colorectal adenomas and carcinomas: an immunocytochemical investigation. Histol Histopathol. 7:543–547. 1992.PubMed/NCBI
48	Yossie Asato de Camargo R, Longatto Filho A, Alves VA, Bisi H, Kanamura CT and Alves Abelin NM: Lactoferrin in thyroid lesions: immunoreactivity in fine needle aspiration biopsy samples. Acta Cytol. 40:408–413. 1996.PubMed/NCBI
49	Tuccari G, Rossiello R and Barresi G: Iron binding proteins in gallbladder carcinomas. An immunocytochemical investigation. Histol Histopathol. 12:671–676. 1997.PubMed/NCBI
50	Tucarri G, Giffre G, Crisafulli C and Barresi G: Immnohistochemical detection of lactoferrin in human astrocytomas and multiforme glioblastomas. Eur J Histochem. 43:317–322. 1999.PubMed/NCBI
51	Bezault J, Bhimani R, Wiprovnick J and Fumanski P: Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 54:2310–2312. 1994.PubMed/NCBI
52	Sakamoto N: Antitumor effect of human lactoferrin against newly established human pancreatic cancer cell line SPA. Gan To Kagaku Ryoho. 25:1557–1563. 1998.(In Japanese).